交易中 11-18 10:57:15 美东时间
+0.719
+0.91%
CG Oncology reports Phase 3 data showing cretostimogene cuts bladder cancer recurrence risk by 68%, advancing two 2027 BLA filings.
11-17 02:09
U.S. stocks fell Monday as tech slid and manufacturing sentiment weakened; oil, gold and silver also declined, while TELUS and H World surged.
11-17 01:05
- High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively- High-Grade - EFS in the overall intention-to-treat
05-15 20:04
CG Oncology (NASDAQ:CGON) announced its Q4 earnings on Friday, February 27, 202...
02-27 21:34
癌症治疗公司CG Oncology(CGON)股价大涨9.1%,此前古根海姆证券以“买入”评级开始覆盖该股,其目标价预示巨大上涨空间。该投行表示看好CG公司针对非肌层浸润性膀胱癌的疗法前景。 海量资讯、精准解读,尽在新浪财经APP 责任编辑:张俊 SF065
2025-10-09 03:25
CG Oncology Inc. announced that its Chairman & CEO, Arthur Kuan, will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on June 10, 2025. The company is focused on developing bladder-sparing therapies for bladder cancer patients.
2025-06-05 12:00
3 analysts have expressed a variety of opinions on CG Oncology (NASDAQ:CGON) ov...
2025-03-08 05:02
HC Wainwright & Co. analyst Andres Maldonado reiterates CG Oncology (NASDAQ:CGON) with a Buy and maintains $75 price target.
2024-09-17 18:44
Roth MKM analyst Benjamin Paluch initiates coverage on CG Oncology (NASDAQ:CGON) with a Buy rating and announces Price Target of $65.
2024-08-28 06:24